At present, ICIs targeting the PD-1/PD-L1 signaling pathway have been applied to patients with various tumors, and have shown good therapeutic effects in malignant melanoma and non-small cell lung cancer (45). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.